How to prioritize treatment in dual malignancy: A case report of patient with non-Hodgkin lymphoma and breast cancer

INTRODUCTION: Clinicians often encounter dilemma upon treating multiple primary malignancies. CASE PRESENTATION: We report a case of a female patient, 72, complained of a lump under her left eye since January 2019. Patient was diagnosed with infiltrating ductal carcinoma grade III of the right breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Chomariyati, Alvi, Diansyah, Muhammad Noor, Amrita, Putu Niken Ayu, Romadhon, Pradana Zaky, Yudho Bintoro, Siprianus Ugroseno, Ashariati, Ami, Savitri, Merlyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486382/
https://www.ncbi.nlm.nih.gov/pubmed/36147133
http://dx.doi.org/10.1016/j.amsu.2022.104300
Descripción
Sumario:INTRODUCTION: Clinicians often encounter dilemma upon treating multiple primary malignancies. CASE PRESENTATION: We report a case of a female patient, 72, complained of a lump under her left eye since January 2019. Patient was diagnosed with infiltrating ductal carcinoma grade III of the right breast in June 2018 with ER+, PR+, and HER2-, treated with hormonal treatment. Histopathology examination of the lump revealed Non Hodgkin Lymphoma (NHL), B cell type, high grade. Patients received rituximab, cyclophosphamide, epirubicin, vincristin, and prednisone (RHCOP) for 6 cycles to overcome lymphoma then received hormonal therapy afterwards. CLINICAL DISCUSSION: According to earlier published case reports, it's advised to start hormonal therapy after RHCOP. The survival time was 21 months (5.1–114.7 months) with 5-year overall survival 29% CONCLUSION: Unfortunately, we could not have a follow-up on the patient after finishing 6 cycles of RHCOP due to the COVID-19 pandemic situation.

Ejemplares similares